ADVERTISEMENT
Clinical Trial Update
Safety and Efficacy Findings from the SPIRIT 48 Trial of the Xience 48 mm Drug-Eluting Stent
05/19/2023
The prospective, single-arm, open-label SPIRIT 48 trial evaluated the safety and efficacy of the Xience Skypoint 48 mm drug-eluting stent (Abbott Vascular) in subjects with coronary artery disease with long de novo native coronary lesions.
Lead researcher Dr. Ki Park discusses the trial and next steps.
